Matthew Taub, MD
Hematology & Oncology · Pembroke Pines, FLNPI 1396784807
Payments from drug & device makers
Across 1,439 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Pfizer$2K
- Johnson & Johnson$2K
- AstraZeneca$2K
- Bristol Myers Squibb$2K
- Pharmacosmos Therapeutics Inc.$2K
- plus $19K from 54 others
What the payments were for
- Speaking & faculty fees$1,5005%
- Food & beverage$29,04790%
- Education$9543%
- Other$7812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$1,500
- Tavalisse$909
- myRisk$163
- IMBRUVICA$125
- Tepmetko$125
- XT CDX$123
- MI CANCER SEEK$108
- CABLIVI$102
How this compares
$32,282 in reported general payments places this provider in the 55th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 125 | $1,870,056 |
| PomalystPomalidomide | 36 | $784,902 |
| ImbruvicaIbrutinib | 40 | $680,804 |
| XtandiEnzalutamide | 47 | $667,998 |
| RevlimidLenalidomide | 39 | $660,509 |
| BrukinsaZanubrutinib | 47 | $638,692 |
| CalquenceAcalabrutinib Maleate | 38 | $591,455 |
| TagrissoOsimertinib Mesylate | 26 | $488,548 |
| LynparzaOlaparib | 29 | $433,191 |
| JakafiRuxolitinib Phosphate | 20 | $404,294 |
| CabometyxCabozantinib S-Malate | 13 | $339,763 |
| VonjoPacritinib Citrate | 13 | $329,989 |
| VerzenioAbemaciclib | 16 | $248,494 |
| InqoviDecitabine/Cedazuridine | 19 | $154,718 |
| VenclextaVenetoclax | 14 | $129,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Lynparza | $2,234 | $1,513,19593 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,546 | $784,90236 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $62 | $680,80440 claims |
| Astellas Pharma US IncXtandi | $248 | $667,99847 claims |
| Bristol Myers SquibbRevlimid | $1,622 | $660,50939 claims |
| Beigene USA, Inc.Brukinsa | $287 | $638,69247 claims |
| Incyte CorporationJakafi | $530 | $404,29420 claims |
| Exelixis Inc.Cabometyx | $177 | $339,76313 claims |
| Lilly USA, LLCVerzenio | $386 | $248,49416 claims |
| AmgenVectibix, Xgeva | $711 | $163,55430 claims |
| Taiho Oncology, Inc.Inqovi | $407 | $154,71819 claims |
| AbbVieVenclexta | $616 | $129,23814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Pembroke Pines
- Aurelio CastrellonPembroke Pines$2.4M
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.